FDA Determines Regulatory Review Period for Multihance Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the patent extension of the medical imaging agent Multihance, as required by law, following a submission to the Director of Patents and Trademarks at the US Department of Commerce.